Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
ACS Nano ; 18(11): 8337-8349, 2024 Mar 19.
Article in English | MEDLINE | ID: mdl-38437640

ABSTRACT

The combination of anti-rheumatoid arthritis (RA) drugs methotrexate (MTX) and baricitinib (BTN) has been reported to improve RA treatment efficacy. However, study on the strategy of combination is elusive when considering the benefit of the synergy between MTX and BTN. In this study, we found that the N-heterocyclic rings in the MTX and BTN offer hydrogen bonds and π-π stacking interactions, driving the formation of exquisite vesicular morphology of nanovesicles, denoted as MB NVs. The MB NVs with the MTX/BTN weight ratio of 2:1, MB NVs (2:1), showed an improved anti-RA effect through the synergy between the anti-inflammatory and antiproliferative responses. This work presents that the intermolecular interactions between drug molecules could mediate the coassembly behavior into nanomedicine as well as the therapy synergy both in vitro and in vivo, which may provide further understanding on the rational design of combination nanomedicine for therapeutic purposes.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Azetidines , Purines , Pyrazoles , Sulfonamides , Humans , Methotrexate/pharmacology , Methotrexate/therapeutic use , Antirheumatic Agents/pharmacology , Antirheumatic Agents/therapeutic use , Nanomedicine , Arthritis, Rheumatoid/drug therapy , Treatment Outcome , Drug Therapy, Combination
SELECTION OF CITATIONS
SEARCH DETAIL